Hepatitis C virus interacts with human platelet glycoprotein VI

Area of Science:

• Virology
• Immunology
• Hematology

Background:

• Hepatitis C virus (HCV) is known to interact with human platelets in vivo.
• Platelets may serve as a transport mechanism for infectious virions to the liver.

Purpose of the Study:

• To analyze the binding of native Hepatitis C virus (HCV) particles to platelet membrane glycoprotein VI (GPVI).
• To investigate the role of GPVI in HCV-mediated viral transport and persistence.

Main Methods:

• Pull-down assays and ELISA were used to analyze HCV and recombinant human GPVI (hD1D2) interaction.
• Binding inhibition assays with anti-hD1D2 antibodies were performed.
• Comparative analysis of human and murine D1D2 binding to HCV.

Main Results:

• Consistent interaction observed between HCV and recombinant human GPVI (hD1D2).
• Specific binding of 2-7% of HCV particles to hD1D2.
• Binding was dose-dependently inhibited by anti-hD1D2 antibodies, and human D1D2 showed significantly higher binding than murine D1D2, indicating specificity.
• Both D1 and D2 domains of GPVI are crucial for efficient HCV binding.

Conclusions:

• Glycoprotein VI (GPVI) acts as a platelet surface ligand for Hepatitis C virus (HCV).
• This interaction likely plays a role in the viral transport and persistence of HCV.
• Targeting the HCV-GPVI interaction could offer new therapeutic strategies.